These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 18257600)

  • 21. β-blockers and their mortality benefits: underprescribed in heart failure and chronic obstructive pulmonary disease.
    Rutten FH
    Future Cardiol; 2011 Jan; 7(1):43-53. PubMed ID: 21174509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers.
    Brooks TW; Creekmore FM; Young DC; Asche CV; Oberg B; Samuelson WM
    Pharmacotherapy; 2007 May; 27(5):684-90. PubMed ID: 17461703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges in the Management of Patients with Chronic Obstructive Pulmonary Disease and Heart Failure With Reduced Ejection Fraction.
    Jaiswal A; Chichra A; Nguyen VQ; Gadiraju TV; Le Jemtel TH
    Curr Heart Fail Rep; 2016 Feb; 13(1):30-6. PubMed ID: 26780914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies.
    Du Q; Sun Y; Ding N; Lu L; Chen Y
    PLoS One; 2014; 9(11):e113048. PubMed ID: 25427000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. β-Blockers and the Rate of Chronic Obstructive Pulmonary Disease Exacerbations.
    Mersfelder TL; Shiltz DL
    Ann Pharmacother; 2019 Dec; 53(12):1249-1258. PubMed ID: 31271049
    [No Abstract]   [Full Text] [Related]  

  • 26. Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease.
    Petta V; Perlikos F; Loukides S; Bakakos P; Chalkias A; Iacovidou N; Xanthos T; Tsekoura D; Hillas G
    Heart Fail Rev; 2017 Nov; 22(6):753-763. PubMed ID: 28840400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease.
    Campo G; Pavasini R; Biscaglia S; Contoli M; Ceconi C
    Eur Heart J Cardiovasc Pharmacother; 2015 Jul; 1(3):205-11. PubMed ID: 27533997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardioselective beta-blockers for chronic obstructive pulmonary disease.
    Salpeter SS; Ormiston T; Salpeter E; Poole P; Cates C
    Cochrane Database Syst Rev; 2002; (2):CD003566. PubMed ID: 12076486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Patients with chronic obstructive pulmonary disease and heart disease can benefit from beta-blocker treatment].
    Rasmussen DB; Lange P; Jensen MT
    Ugeskr Laeger; 2015 Sep; 177(38):V02150184. PubMed ID: 26376419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD.
    Dransfield MT; Rowe SM; Johnson JE; Bailey WC; Gerald LB
    Thorax; 2008 Apr; 63(4):301-5. PubMed ID: 17951276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Beta-blockers usage in cardio-vascular diseases co-existing with COPD].
    Walczak D; Kowal A; Jankowska R
    Pol Merkur Lekarski; 2012 Dec; 33(198):338-41. PubMed ID: 23437704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative.
    Coiro S; Girerd N; Rossignol P; Ferreira JP; Maggioni A; Pitt B; Tritto I; Ambrosio G; Dickstein K; Zannad F
    Eur J Heart Fail; 2017 Feb; 19(2):271-279. PubMed ID: 27774703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD.
    Huang YL; Lai CC; Wang YH; Wang CY; Wang JY; Wang HC; Yu CJ; Chen L
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2987-2996. PubMed ID: 29066880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Beta-blocker prescription and chronic obstructive pulmonary disease].
    Ollivier R; Donal E; Delaval P; Daubert JC; Mabo P
    Ann Cardiol Angeiol (Paris); 2007 Nov; 56(5):231-6. PubMed ID: 17854758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis.
    Salpeter SR; Ormiston TM; Salpeter EE; Poole PJ; Cates CJ
    Respir Med; 2003 Oct; 97(10):1094-101. PubMed ID: 14561016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk.
    Brook RD; Anderson JA; Calverley PM; Celli BR; Crim C; Denvir MA; Magder S; Martinez FJ; Rajagopalan S; Vestbo J; Yates J; Newby DE;
    Heart; 2017 Oct; 103(19):1536-1542. PubMed ID: 28416587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular function and prognosis of patients with heart failure coexistent with chronic obstructive pulmonary disease.
    Yoshihisa A; Takiguchi M; Shimizu T; Nakamura Y; Yamauchi H; Iwaya S; Owada T; Miyata M; Abe S; Sato T; Suzuki S; Oikawa M; Kobayashi A; Yamaki T; Sugimoto K; Kunii H; Nakazato K; Suzuki H; Saitoh S; Takeishi Y
    J Cardiol; 2014 Oct; 64(4):256-64. PubMed ID: 24674751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beta-blocker under-use in COPD patients.
    Lim KP; Loughrey S; Musk M; Lavender M; Wrobel JP
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3041-3046. PubMed ID: 29089752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.
    Buhl R; Magder S; Bothner U; Tetzlaff K; Voß F; Loaiza L; Vogelmeier CF; McGarvey L
    Respir Med; 2017 Jan; 122():58-66. PubMed ID: 27993292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.